drugset / Trial / NCT06050668

Essential Amino Acid Supplementation for Femoral Fragility Fractures

NCT06050668 ↗

RandomizedParallel-groupDouble-blindSupportive care

Summary

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

Timeline

Start
2024-06-17
Primary completion
2026-07
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MEND™ Repair and Recover® Unknown 26.7 g Oral